Red Light Holland is an Ontario-based organization advancing a focused strategy within the legal psychedelic sector, centered on consensual data collection and R&D initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences. Following the closing of the acquisition of Filament Health Corp., Filament is now a wholly-owned subsidiary of the Company, bringing together its established Good Manufacturing Practice (“GMP”) production capabilities, regulatory engagement with the U.S. Food and Drug Administration (“FDA”), and a growing global clinical footprint anchored by PEX010, a patented botanical psilocybin drug candidate. In parallel, the Company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands’ legal market and mushroom home grow kits offered through B2B and DTC channels, in compliance with applicable laws.
Be the first to comment